In potentially curable cancers, long-term survival depends not only on the successful treatment of the malignancy but also on the risks associated with treatment-related toxicity, especially cardiotoxicity. Malignant lymphomas affect patients at any age, with acute and late toxicity risks that could have a severe effect on morbidity, mortality, and quality of life. Although our understanding of chemotherapy-associated and radiotherapy-associated cardiovascular disease has advanced considerably, new drugs with potential cardiotoxicity have been introduced for the treatment of lymphomas. In this Review, we summarise the mechanisms of treatment-related cardiac injury, available clinical data, and protocols for optimising cardioprotection in lymphomas. We discuss ongoing research strategies to advance our knowledge of the molecular basis of drug-induced and radiation-induced toxicity. Additionally, we emphasise the potential for personalised follow-up and early detection, including the role of biomarkers and novel diagnostic tests, highlighting the role of the cardio-oncology team.

中文翻译：

---

淋巴瘤心脏保护的综合方法。

在潜在可治愈的癌症中，长期生存不仅取决于恶性肿瘤的成功治疗，还取决于与治疗相关的毒性，尤其是心脏毒性相关的风险。恶性淋巴瘤影响任何年龄的患者，具有急性和晚期毒性风险，可能对发病率、死亡率和生活质量产生严重影响。尽管我们对化疗相关和放疗相关心血管疾病的理解有了很大进步，但已经引入了具有潜在心脏毒性的新药来治疗淋巴瘤。在这篇综述中，我们总结了治疗相关心脏损伤的机制、可用的临床数据和优化淋巴瘤心脏保护的方案。我们讨论了正在进行的研究策略，以提高我们对药物诱导和辐射诱导毒性的分子基础的认识。此外，我们强调了个性化随访和早期检测的潜力，包括生物标志物和新型诊断测试的作用，突出了心脏肿瘤学团队的作用。